Somaxon Pharmaceuticals
AboutProductsPartnersInvestorsNewsCareersContact

Overview
Press Releases
Stock Information
SEC Filings
Analyst Coverage
Webcasts/ IR Events
Investor FAQs
Request for Information


Join Our Mailing List

Please join our mailing list if you wish to receive news regarding Somaxon and its products.



Webcasts/ IR Events

Upcoming Events
Details on upcoming events are not yet available.

Archived Events
Somaxon Pharmaceuticals 2012 Third Quarter Financial Results Conference Call
Oct 31, 2012 1:30 PM PT
Webcast Listen to webcast
Stifel Nicolaus 2012 Healthcare Conference
Sep 6, 2012 10:20 AM ET
Webcast Listen to webcast
Somaxon Pharmaceuticals 2012 Second Quarter Financial Results Conference Call
Aug 7, 2012 4:30 PM ET
Webcast Listen to webcast
Somaxon Pharmaceuticals 2011 Third Quarter Financial Results Conference Call
Nov 3, 2011 5:30 AM PT
Webcast Listen to webcast
Somaxon Pharmaceuticals Special Conference Call
Oct 4, 2011 5:30 AM PT
Show Additional Information
Webcast Listen to webcast
Barclays Capital 2011 Global Healthcare Conference
Mar 16, 2011 3:45 PM ET
Show Additional Information
Webcast Listen to webcast
Roth 23rd Annual OC Growth Stock Conference
Mar 14, 2011 12:30 PM ET
Show Additional Information
Webcast Listen to webcast
Cowen and Company 31st Annual Health Care Conference
Mar 7, 2011 4:00 PM ET
Show Additional Information
Webcast Listen to webcast
Somaxon Pharmaceuticals 2010 Fourth Quarter Financial Results Conference Call
Mar 3, 2011 4:30 PM ET
Webcast Listen to webcast
13th Annual BIO CEO & Investor Conference
Feb 14, 2011 10:30 AM ET
Speaker: Richard W. Pascoe, President and Chief Executive Officer
Webcast Listen to webcast
Somaxon Rings the NASDAQ Stock Market Opening Bell
Dec 3, 2010 9:25 AM ET
Webcast Listen to webcast
Piper Jaffray 22nd Annual Health Care Conference
Dec 1, 2010 1:00 PM ET
Show Additional Information
Speaker: Richard W. Pascoe, President and Chief Executive Officer
Webcast Listen to webcast
Somaxon Pharmaceuticals 2010 Third Quarter Financial Results Conference Call
Nov 9, 2010 4:30 PM ET
Webcast Listen to webcast
UBS Global Life Sciences Conference
Sep 21, 2010 4:30 PM ET
Webcast Listen to webcast
Somaxon Pharmaceuticals 2010 First Quarter Financial Results Conference Call
May 11, 2010 4:30 PM ET
Webcast Listen to webcast
Somaxon Announces FDA Approval of Silenor for the Treatment of Insomnia
Mar 18, 2010 9:00 AM PT
Webcast Listen to webcast
Somaxon Pharmaceuticals 2009 Third Quarter Financial Results Conference Call
Nov 5, 2009 1:30 PM PT
Webcast Listen to webcast
The 8th Annual BIO Investor Forum
Oct 28, 2009 3:00 PM PT
Webcast Listen to webcast
Somaxon Pharmaceuticals 2009 Second Quarter Financial Results Conference Call
Aug 6, 2009 4:30 PM ET
Webcast Listen to webcast
Somaxon Pharmaceuticals 2009 First Quarter Financial Results Conference Call
May 7, 2009 1:30 PM PT
Webcast Listen to webcast
Somaxon Pharmaceuticals to Report 2008 Fourth Quarter And Full Year Financial Results
Mar 12, 2009 4:30 PM ET
Webcast Listen to webcast
Somaxon Special Conference Call
Feb 26, 2009 1:30 PM PT
Webcast Listen to webcast
FDA Extends Review of Somaxon Pharmaceuticals New Drug Application for Silenor Conference Call
Nov 24, 2008 9:00 AM ET
Webcast Listen to webcast

Add to Briefcase = add file to Briefcase

Forward-Looking Statements

Somaxon cautions you that statements included in the company's conference calls, press releases and other materials posted on, or available through, this website that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Somaxon that any of its plans will be achieved. Actual results may differ materially from those discussed in the conference calls, press releases and other materials posted on, or available through, this website due to the risks and uncertainties inherent in Somaxon's business including, without limitation: the progress and timing of its clinical trials and regulatory approval process; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of its product candidates that could delay or prevent regulatory approval, product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its product candidates; and other risks detailed in Somaxon's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for its most recently completed fiscal year. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Somaxon undertakes no obligation to revise or update such statements to reflect events or circumstances after the date made. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.